Efficacy of cilostazol in patients with acute coronary syndrome after percutaneous coronary intervention

American Journal of Therapeutics

Volumn 20, Issue 2, 2013, Pages 151-153

  Hu, Taohong ^a   Ma, Huili ^a   Li, Huijun ^a   Ren, Jianghua ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Cilostazol; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; SUDDEN DEATH; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD COAGULATION; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875231148     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31825a3616     Document Type: Article

References (15)

1. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826-2832
2. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942-1947
3. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol. 2006;19: 439-448
4. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the armyda-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation. 2005;111:2099-2106
5. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420
6. von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007;28:1814-1819
7. Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia. 2001;44:1034-1042
8. Ishizaka N, Taguchi J, Kimura Y, et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis. 1999; 142:41-46
9. Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J. 2007;71:1867-1872
10. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 1999;96: 261-268
11. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis. J Am Coll Cardiol. 2005;46:1833-1837
12. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the optimizing antiplatelet therapy in diabetes mellitus (optimus) study. Circulation. 2007;115: 708-716
13. Ge J, Han Y, Jiang H, et al. A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: Long-Term clinical and angiographic outcome. J Cardiovasc Pharmacol. 2005;46: 162-166
14. Grouse JR III, Allan MC, Elam MB. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication. J Clin Pharmacol. 2002;42:1291-1298
15. Han YL, Wu ZF, Zhang XL, et al. Matrix metalloproteinase-1 gene -519a/g polymorphism and the risk of coronary heart disease in northern chinese han population [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36:195-198